Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Meyer

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
The Journal of Clinical Psychiatry|November 11, 2010
Use of clinical markers to identify metabolic syndrome in antipsychotic-treated patientsHua Jin, Jonathan Meyer, Sunder Mudaliar, et al.
Molecular Genetics and Metabolism Reports|June 9, 2025
Real-world clinical outcomes in adult patients with Fabry disease: A 20-year retrospective observational cohort study from a single centreEamon P McCarron, Rajkumar Chinnadurai, Jonathan Meyer, et al.
Journal of Psychiatric Practice|January 25, 2006
Prevalence of the metabolic syndrome in veterans with schizophreniaJonathan Meyer, Catherine Loh, Susan G Leckband, et al.
Molecular Genetics and Metabolism Reports|May 25, 2026
Effectiveness and tolerability of migalastat in adult Fabry disease: A single regional centre experienceEamon P McCarron, Rajkumar Chinnadurai, Karolina M Stepien, et al.
Journal of Pediatric Nursing|September 11, 2017
Recommendations for the Establishment of Disorders/Differences of Sex Development Interdisciplinary Care Clinics for YouthDana M Bakula, Christina M Sharkey, Cortney Wolfe-Christensen, et al.
Advances in Therapy|September 8, 2025
Switching Patients with Schizophrenia from Intramuscular Paliperidone Palmitate Once Monthly to TV-46000, a Long-Acting Subcutaneous Antipsychotic: Population Pharmacokinetic-Based StrategiesItay Perlstein, Jonathan Meyer, Ziqi Yue, et al.
Schizophrenia Research|February 22, 2011
The association between weight change and symptom reduction in the CATIE schizophrenia trialEric Hermes, Henry Nasrallah, Vicki Davis, et al.
Neurology and Therapy|October 26, 2025
Population Pharmacokinetic-Based Strategies for Switching Patients with Schizophrenia Between Long-Acting Injectable Formulations of Risperidone: R064766 or RBP-7000 to TV-46000Itay Perlstein, Jonathan Meyer, Sharath Kumar, et al.
International Journal of Pharmaceutics|May 22, 2024
Mechanistic modeling of twin screw wet granulation for pharmaceutical formulations: Calibration, sensitivity analysis, and model-driven workflowNeeru Bala, Jeremiah Corrigan, Jonathan Meyer, et al.
The American Journal of Cardiology|June 22, 2022
Impact of Transcatheter Aortic Valve Implantation Among Patients With Co-existing Mild to Moderate Mitral RegurgitationAamir H Twing, Sanket Gokhale, Brody Slostad, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
The Journal of Clinical Psychiatry|November 11, 2010
Use of clinical markers to identify metabolic syndrome in antipsychotic-treated patientsHua Jin, Jonathan Meyer, Sunder Mudaliar, et al.
Molecular Genetics and Metabolism Reports|June 9, 2025
Real-world clinical outcomes in adult patients with Fabry disease: A 20-year retrospective observational cohort study from a single centreEamon P McCarron, Rajkumar Chinnadurai, Jonathan Meyer, et al.
Journal of Psychiatric Practice|January 25, 2006
Prevalence of the metabolic syndrome in veterans with schizophreniaJonathan Meyer, Catherine Loh, Susan G Leckband, et al.
Molecular Genetics and Metabolism Reports|May 25, 2026
Effectiveness and tolerability of migalastat in adult Fabry disease: A single regional centre experienceEamon P McCarron, Rajkumar Chinnadurai, Karolina M Stepien, et al.
Journal of Pediatric Nursing|September 11, 2017
Recommendations for the Establishment of Disorders/Differences of Sex Development Interdisciplinary Care Clinics for YouthDana M Bakula, Christina M Sharkey, Cortney Wolfe-Christensen, et al.
Advances in Therapy|September 8, 2025
Switching Patients with Schizophrenia from Intramuscular Paliperidone Palmitate Once Monthly to TV-46000, a Long-Acting Subcutaneous Antipsychotic: Population Pharmacokinetic-Based StrategiesItay Perlstein, Jonathan Meyer, Ziqi Yue, et al.
Schizophrenia Research|February 22, 2011
The association between weight change and symptom reduction in the CATIE schizophrenia trialEric Hermes, Henry Nasrallah, Vicki Davis, et al.
Neurology and Therapy|October 26, 2025
Population Pharmacokinetic-Based Strategies for Switching Patients with Schizophrenia Between Long-Acting Injectable Formulations of Risperidone: R064766 or RBP-7000 to TV-46000Itay Perlstein, Jonathan Meyer, Sharath Kumar, et al.
International Journal of Pharmaceutics|May 22, 2024
Mechanistic modeling of twin screw wet granulation for pharmaceutical formulations: Calibration, sensitivity analysis, and model-driven workflowNeeru Bala, Jeremiah Corrigan, Jonathan Meyer, et al.
The American Journal of Cardiology|June 22, 2022
Impact of Transcatheter Aortic Valve Implantation Among Patients With Co-existing Mild to Moderate Mitral RegurgitationAamir H Twing, Sanket Gokhale, Brody Slostad, et al.
Pageof 4